Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

Ruxolitinib helped a patient with alopecia areata regrow hair.

Aumolertinib effectively controls lung cancer and improves quality of life.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

Ivarmacitinib may effectively treat complex atopic dermatitis and related hair loss.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

EGFR inhibitors can cause unusual localized hair growth.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.